文章：

抗血管超声（AVUS）在肝细胞癌（HCC）中的疗效评估

Efficacy of Antivascular Ultrasound (AVUS) in Hepatocellular Carcinoma (HCC)

原文发布日期：7 November 2024

DOI: 10.3390/cancers16223756

类型: Article

开放获取: 是

英文摘要：

Background: Hepatocellular carcinoma (HCC) is a prevalent type of primary liver cancer and one of the leading causes of cancer-related mortality worldwide. Antivascular Ultrasound (AVUS) is a novel therapy approach that utilizes the mechanical and thermal interactions between ultrasound and microbubbles to disrupt tumor vasculature or potentiate effects of chemotherapy or radiation therapy in a dose-dependent fashion. In this review, we aim to illustrate the mechanisms of AVUS, focusing on the preclinical and clinical evidence of AVUS applications in HCC. Methods: Peer-reviewed publications pertaining to the use of AVUS in HCC were collected and analyzed. Results: 12 preclinical studies and 1 clinical trial were analyzed. At lower energy levels, AVUS can enhance tumor perfusion, facilitating the delivery of chemotherapy agents and resulting in improved therapeutic outcomes. Conversely, at higher energy levels, AVUS can disrupt tumor perfusion, leading to ischemic damage of the tumors. Combining AVUS with other therapeutic approaches, such as chemotherapy, radiation therapy, and transarterial radioembolization (TARE), can synergistically enhance therapeutic outcomes. Conclusions: AVUS is a promising novel treatment modality for HCC. Current evidence suggests that AVUS exhibits a dose-dependent nature, making it a versatile approach that can be effectively combined with other therapeutic regimens. Further clinical studies and long-term follow-ups are needed to establish the optimal clinical protocol and safety profile of AVUS.

摘要翻译： 

背景：肝细胞癌（HCC）是一种常见的原发性肝癌，也是全球癌症相关死亡的主要原因之一。抗血管超声（AVUS）是一种新型治疗方法，利用超声波与微泡之间的机械和热相互作用，以剂量依赖的方式破坏肿瘤血管系统或增强化疗或放疗的效果。本综述旨在阐述AVUS的作用机制，重点关注其在HCC中应用的临床前和临床证据。方法：收集并分析了与AVUS在HCC中应用相关的同行评审文献。结果：共分析了12项临床前研究和1项临床试验。在较低能量水平下，AVUS可增强肿瘤灌注，促进化疗药物的输送，从而改善治疗效果。相反，在较高能量水平下，AVUS可破坏肿瘤灌注，导致肿瘤缺血性损伤。将AVUS与其他治疗方法（如化疗、放疗和经动脉放射栓塞术）相结合，可协同增强治疗效果。结论：AVUS是一种有前景的HCC新型治疗方式。现有证据表明，AVUS具有剂量依赖性，使其成为一种多功能方法，可与其他治疗方案有效结合。需要进一步的临床研究和长期随访来确定AVUS的最佳临床方案和安全性。

原文链接：

Efficacy of Antivascular Ultrasound (AVUS) in Hepatocellular Carcinoma (HCC)